AstraZeneca

News

AZ gets landmark approval for Imfinzi/Lynparza combo

AstraZeneca has become the first company to get approval for the combination of an immunotherapy with a PARP inhibitor for treating endometrial cancer.

News

Image of the word No in gold neon lights

NICE blocks Enhertu use after pricing talks break down

NICE and drugmakers AstraZeneca and Daiichi Sankyo have all expressed their disappointment at being unable to agree on a price for Enhertu that would allow it to be used on the NHS for peop

News

AMPLIFY results dial up Calquence's potential in CLL

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuste

News

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

FDA reviewers were so frustrated by AstraZeneca's application for Imfinzi as a treatment before and after surgery for resectable non-small cell lung cancer (NSCLC) that they voted for a ret

News

European big pharmas raise guidance on stronger sales

AstraZeneca, Roche, and Sanofi released their second-quarter results today, with a common theme – strong sales growth that caused them to raise their financial guidance for the year.

News

MSD stakes claim to RSV prevention market for infants

MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-gro

AZ gets landmark approval for Imfinzi/Lynparza combo

NICE blocks Enhertu use after pricing talks break down

AMPLIFY results dial up Calquence's potential in CLL

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

European big pharmas raise guidance on stronger sales

MSD stakes claim to RSV prevention market for infants

AZ claims another win for Imfinzi in frontline liver cancer

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks